Engitix is a UK-based biotechnology company using its proprietary technology to decellularise human organs, such as livers, for development of a range of
off-the-shelf and bespoke products for use in drugs and diagnostics research, and in therapeutic applications. Disease model products – cell-cultures and ECM gel – will be sold directly and in partnership with an established organisation, whilst biomarker assay sales, development of bioartificial liver products, and R&D for bioengineered whole-livers will be achieved solely in partnership. The company is a spin out from the UCL medical school and was incorporated in 2016.